188 related articles for article (PubMed ID: 11850545)
21. The performance of semi-quantitative differential PCR is similar to that of real-time PCR for the detection of the MYCN gene in neuroblastomas.
Souza AC; Souza DR; Sanabani SS; Giorgi RR; Bendit I
Braz J Med Biol Res; 2009 Sep; 42(9):791-5. PubMed ID: 19738985
[TBL] [Abstract][Full Text] [Related]
22. Physical mapping of the DDX1 gene to 340 kb 5' of MYCN.
Kuroda H; White PS; Sulman EP; Manohar CF; Reiter JL; Cohn SL; Brodeur GM
Oncogene; 1996 Oct; 13(7):1561-5. PubMed ID: 8875996
[TBL] [Abstract][Full Text] [Related]
23. Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues.
Misra DN; Dickman PS; Yunis EJ
Diagn Mol Pathol; 1995 Jun; 4(2):128-35. PubMed ID: 7551293
[TBL] [Abstract][Full Text] [Related]
24. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
25. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas.
De Preter K; Speleman F; Combaret V; Lunec J; Board J; Pearson A; De Paepe A; Van Roy N; Laureys G; Vandesompele J
J Clin Oncol; 2005 May; 23(13):3167-8; author reply 3168-70. PubMed ID: 15860893
[No Abstract] [Full Text] [Related]
26. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
27. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections.
Thorner PS; Ho M; Chilton-MacNeill S; Zielenska M
Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319
[TBL] [Abstract][Full Text] [Related]
28. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method.
Bhargava R; Oppenheimer O; Gerald W; Jhanwar SC; Chen B
Diagn Mol Pathol; 2005 Jun; 14(2):72-6. PubMed ID: 15905689
[TBL] [Abstract][Full Text] [Related]
29. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.
Crabbe DC; Peters J; Seeger RC
Diagn Mol Pathol; 1992 Dec; 1(4):229-34. PubMed ID: 1342970
[TBL] [Abstract][Full Text] [Related]
30. Differential polymerase chain reaction with serial dilutions for quantification of MYCN gene amplification in neuroblastoma.
Gallego S; Reventos J; Sanchez de Toledo J; Munell F
Anticancer Res; 1998; 18(2A):1211-5. PubMed ID: 9615790
[TBL] [Abstract][Full Text] [Related]
31. The neuroblastoma amplified gene, NAG: genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma.
Scott DK; Board JR; Lu X; Pearson AD; Kenyon RM; Lunec J
Gene; 2003 Mar; 307():1-11. PubMed ID: 12706883
[TBL] [Abstract][Full Text] [Related]
32. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
[TBL] [Abstract][Full Text] [Related]
33. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
[TBL] [Abstract][Full Text] [Related]
34. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
35. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
36. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study.
Mathew P; Valentine MB; Bowman LC; Rowe ST; Nash MB; Valentine VA; Cohn SL; Castleberry RP; Brodeur GM; Look AT
Neoplasia; 2001; 3(2):105-9. PubMed ID: 11420745
[TBL] [Abstract][Full Text] [Related]
37. Automatic quantification of gene amplification in clinical samples by IQ-FISH.
Narath R; Lörch T; Rudas M; Ambros PF
Cytometry B Clin Cytom; 2004 Jan; 57(1):15-22. PubMed ID: 14696059
[TBL] [Abstract][Full Text] [Related]
38. Fast detection of MYCN copy number alterations in brain neuronal tumors by real-time PCR.
Malakho SG; Korshunov A; Stroganova AM; Poltaraus AB
J Clin Lab Anal; 2008; 22(2):123-30. PubMed ID: 18348317
[TBL] [Abstract][Full Text] [Related]
39. Morphologic and molecular cytogenetics in neuroblastoma.
Avet-Loiseau H; Venuat AM; Benard J; Leibovitch MP; Hartmann O; Bernheim A
Cancer; 1995 Apr; 75(7):1694-9. PubMed ID: 8826929
[TBL] [Abstract][Full Text] [Related]
40. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
